Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight brokerages that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $46.43.

OTLK has been the subject of a number of research reports. HC Wainwright lifted their target price on Outlook Therapeutics to $30.00 and gave the stock a "buy" rating in a report on Monday, March 25th. Brookline Capital Management raised shares of Outlook Therapeutics from a "hold" rating to a "buy" rating and set a $31.40 price objective on the stock in a report on Thursday, January 25th. Chardan Capital raised shares of Outlook Therapeutics from a "neutral" rating to a "buy" rating and set a $60.00 target price for the company in a report on Thursday, February 15th. Capital One Financial restated an "overweight" rating on shares of Outlook Therapeutics in a research report on Friday, February 16th. Finally, Ascendiant Capital Markets increased their price target on Outlook Therapeutics from $30.00 to $40.00 and gave the stock a "buy" rating in a research report on Friday, December 29th.

Outlook Therapeutics Price Performance

Outlook Therapeutics stock traded down $0.34 during mid-day trading on Friday, reaching $8.70. 267,111 shares of the company traded hands, compared to its average volume of 1,716,687. The firm's fifty day moving average is $8.57 and its two-hundred day moving average is $8.27. The company has a market capitalization of $113.19 million, a price-to-earnings ratio of -2.18 and a beta of 0.04. Outlook Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $40.60.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last released its earnings results on Wednesday, February 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.20. As a group, equities research analysts predict that Outlook Therapeutics will post -2.99 earnings per share for the current year.

Hedge Funds Weigh In On Outlook Therapeutics

Hedge funds have recently bought and sold shares of the business. Scotia Capital Inc. grew its position in shares of Outlook Therapeutics by 420.9% in the third quarter. Scotia Capital Inc. now owns 338,439 shares of the company's stock valued at $75,000 after purchasing an additional 273,463 shares during the period. Gables Capital Management Inc. raised its stake in Outlook Therapeutics by 132.3% in the 3rd quarter. Gables Capital Management Inc. now owns 154,500 shares of the company's stock valued at $34,000 after purchasing an additional 88,000 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in Outlook Therapeutics by 31.8% in the 4th quarter. Alliancebernstein L.P. now owns 43,900 shares of the company's stock valued at $47,000 after purchasing an additional 10,600 shares in the last quarter. Virtu Financial LLC acquired a new stake in Outlook Therapeutics during the 4th quarter worth $40,000. Finally, Citadel Advisors LLC grew its holdings in shares of Outlook Therapeutics by 210.4% during the third quarter. Citadel Advisors LLC now owns 32,801 shares of the company's stock worth $40,000 after buying an additional 22,232 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company's stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.